Canchen Tech (CANCHEN TECH) has closed a seed-to-angel series of rounds worth tens of millions of yuan, with investors including Orient Securities Capital, SongHe Capital, Tsinghua-based funds and TusStar, the company told Leiphone.
It is building a system-level virtual-organ simulation platform — digital twins spanning molecule, cell, tissue and organ — to replace parts of traditional animal testing in preclinical drug evaluation and early disease screening.
The timing is regulatory. In July 2026 China’s CDE published a draft ‘Pioneer Plan’ that, for the first time, admits AI virtual-organ digital twins into the statutory non-clinical evidence system for drugs. The FDA, EMA and the UK’s MHRA had already greenlit similar paths.
Canchen’s edge, investors say, is a closed loop linking simulation, wet-lab experiments and clinical front-validation, not just theory. Its architecture runs three layers: a multi-omics life foundation model, organ twins (brain, gut, liver), and whole-lifecycle multi-organ reasoning. The team published embryo full-cycle 3D dynamic models in Cell.
Partnerships already span a Southwest national compute centre, BGI’s Sanya institute, and top-tier hospitals for clinical validation of neonatal disease screening. The window is open; the race now is who turns the algorithm into a standard product pharma will trust.
Original report: Leiphone.
Translated and adapted from Leiphone (leiphone.com).